Researchers will dose participants with psilocybin while they receive psychological support. The firm hopes more countries will join the project as and when respective health bodies approve the use of psilocybin for clinical trials.  

“If our studies are successful, we could be applying for marketing authorization in two to three years,” she said, describing depression as “a huge unmet need with 300 million patients worldwide; 100 million of these have treatment-resistant depression and don’t respond to existing treatments.”

Original Article (Newsweek):
FDA approves psychedelic magic mushrooms ingredient psilocybin for depression trial
Artwork Fair Use: Jynto